Lydia Meder

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Sandra Ortiz‐Cuaran, Matthias Scheffler, Dennis Plenker et al. · Clinical Cancer Research · 2016 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Johannes M. Heuckmann, Hyatt Balke‐Want, Florian Malchers et al. · Clinical Cancer Research · 2012 · 259 citations

Medicine, Oncology, Pharmacology +14

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Sampurna Chatterjee, Lukas C. Heukamp, Maike Siobal et al. · Journal of Clinical Investigation · 2013 · 193 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice

Lukas C. Heukamp, Theresa Thor, Alexander Schramm et al. · Science Translational Medicine · 2012 · 179 citations · Full text

Medicine, Cancer Biology, Oncology +15

<scp>NOTCH</scp>, <scp>ASCL1</scp>, p53 and <scp>RB</scp> alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas

Lydia Meder, Katharina König, Luka Ozretić et al. · International Journal of Cancer · 2015 · 177 citations · Full text

Medicine, Molecular Genetics, Oncology +17